Urine DNA Methylation Detection for Hematuria Evaluation

Launched by CHANGHAI HOSPITAL · May 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect bladder cancer and other urinary system cancers in patients who have blood in their urine, a condition known as hematuria. Researchers want to see if testing for certain DNA changes in urine can help identify these cancers more accurately than current methods, which can be invasive and sometimes not very precise. The trial will involve collecting urine samples from participants before they have surgery, and the goal is to determine how well this new test works compared to traditional diagnostic methods.

To be eligible for this study, participants need to be between 18 and 99 years old and have blood in their urine. They should be able to provide a urine sample of about 50 milliliters and agree to participate by signing a consent form. However, people with certain health conditions or other cancers, as well as those with severe urinary infections or who cannot undergo surgery, will not be included. If you join the study, you can expect to help researchers learn more about this non-invasive testing method, which could lead to better detection of urinary cancers in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Aged between 18 and 99 years, with gross or microscopic hematuria (\>3/HP).
• • 2. Able to provide 50ml urine for testing before surgery.
• • 3. Consent to participate in the study and sign the informed consent form.
• Exclusion Criteria:
• • 1. With history of malignancy or concomitant malignancies other than UC.
• • 2. Severe urinary tract infection leading to sepsis.
• • 3. Patients with indwelling catheters, nephrostomy, or cystostomy. 4 Severe liver or kidney failure or other conditions deemed unsuitable for the study.
• • 5. Patients who did not undergo surgical treatment for various reasons. 6. Samples with insufficient DNA content or other quality control failures.